Research and development centered on challenge, overseas expansion and innovation

「Since fiscal 2023, our company has been selected for Theme 6, “Development of Social Implementation Technologies for HCPS-Integrated Human-Cooperative Robotics to Resolve Social Issues Faced by People Across Generations in a Super-Aged Society,” under the Cabinet Office’s Strategic Innovation Creation Program (SIP) Phase 3, “Development of Foundational Technologies and Rules for the Expansion of Human-Cooperative Robotics.” We have continued efforts toward social implementation, including 1) applying the technology to various living spaces such as homes, facilities and workplaces; 2) using HCPS-integrated master-remote control technology (cybernic master-remote technology) integrated with human data, including physiological, physical, behavioral and cognitive, and psychological data; 3) noninvasively collecting and using human data through HCPS-integrated human-cooperative robotics; and 4) linking this work with other related technologies to improve the independence and freedom of older people and people with mobility limitations.」

「この度、再度、当課題全体の予算が変更されたことに伴い、変更契約を締結することとなりましたので、下記のとおりお知らせいたします。」

「Total R&D expenses for the fiscal year amounted to ¥1,000 million, representing 29.7% of total selling, general and administrative expenses and a significant proportion thereof.」

「2025年12月には、AI・ロボット研究の世界をリードする米国カーネギーメロン大学との間で、世界で活発化するAI・ロボットを含むサイバニクス分野（バイオ・医療系とAI・ロボット・情報系の融合）における研究・教育の連携、及び、既存の当社製品や今後の当社製品の全米での社会実装の加速に向けて、戦略的MOUを締結し、ピッツバーグの医療・ヘルスケアエコシステムとも連携し、協働の準備を進めています。」

「R&D expenses of ¥408 million, up 15.3% year on year, were recorded due to the continued development of new products, clinical research and commissioned research. There were no material changes in the company's R&D activities during the six months ended the second quarter.」

「The company was selected for Theme 6, "Development of social implementation technologies for human-cooperative robotics integrating HCPS to solve social issues faced by people across generations in a super-aging society," under the Cabinet Office's Strategic Innovation Creation Program (SIP) Phase 3, "Development of foundational technologies and rules for expanding human-cooperative robotics."」

「R&D expenses of ¥354 million, up 6.4% year on year, were recorded due to the continued development of new products, clinical research and commissioned research.」

「R&D expenses of ¥174 million, up 15.6% year on year, were recorded due to the continued development of new products, clinical research and commissioned research.」

「R&D expenses of ¥333 million, down 4.9% year on year, were recorded due to the continued development of new products, clinical research and commissioned research.」

「R&D expenses of ¥151 million, down 19.5% year on year, were recorded due to the continued development of new products, clinical research and commissioned research.」

「R&D expenses of ¥523 million, up 2.4% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research.」

「To accelerate the creation of the cybernic industry, the Group is advancing research and product development, business promotion, and business partnerships in parallel.」

「R&D expenses of ¥372 million, down 25.8% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research.」

「R&D expenses of ¥998 million, up 19.8% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research.」

「R&D expenses of ¥501 million, up 27.8% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research.」

「R&D expenses of ¥217 million, up 9.2% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research under JST's ImPACT program for an innovative cybernic system to achieve a society with zero heavy-care needs.」

「The group's research and development activities are guided by three keywords: challenge, innovation and global. As an innovation company supporting a super-aging society, it conducts multifaceted R&D to drive its business and achieve social implementation, including the creation of innovative technologies and new industries.」

「R&D expenses of ¥394 million, down 7.9% year on year, were recorded due to the continued in-house development of new products and the implementation of commissioned research under JST's ImPACT program for an innovative cybernic system to achieve a society with zero heavy-care needs.」

「The group's research and development activities are guided by three keywords: challenge, innovation and global. As an innovation company supporting a super-aging society, it conducts multifaceted R&D to drive its business and achieve social implementation, including the creation of innovative technologies and new industries.」

「R&D expenses increased to ¥655 million, up 11.6% year on year, mainly due to the acceleration of commissioned research under JST's ImPACT program for an innovative cybernic system to achieve a society with zero heavy-care needs.」

「R&D expenses increased to ¥428 million, up 35.6% year on year, mainly due to the acceleration of commissioned research under JST's ImPACT program for an innovative cybernic system to achieve a society with zero heavy-care needs.」

「R&D expenses increased significantly to ¥232 million, up 84.8% year on year, mainly due to the acceleration of commissioned research under JST's ImPACT program.」

「The group's research and development activities are guided by three keywords: challenge, meaning taking on challenges; overseas expansion; and innovation. As an innovation company supporting an aging society, it conducts multifaceted R&D and business-strategy research to drive its business and achieve social implementation, including the creation of innovative technologies and new industries.」